{"collectionById":{"c94d0566-82dc-4df5-b63f-8746938a46da":{"id":"c94d0566-82dc-4df5-b63f-8746938a46da","name":"Highlighted article","fieldSchemas":[{"id":"f7fc8c5b-ff56-4aef-a73a-481c7cc7bcb9","name":"Category","type":"plain_text"},{"id":"b75c275d-e282-4e1a-841a-992d0d66c1da","name":"Title","type":"plain_text","role":"primary"},{"id":"c942b06b-25fc-4a49-8efd-0bcdaff0ec1c","name":"Slug","type":"slug","role":"slug"},{"id":"62fe7219-3878-49d9-a8af-86d06cba35bb","name":"Article body","type":"rich_text"},{"id":"200f29aa-6f6f-4d59-b2bf-4203c876802f","name":"Image","type":"image"},{"id":"ef193eef-561d-489f-9350-39bd897eb652","name":"Date","type":"date"},{"id":"6f2f7e7b-089a-466a-9e25-ad26df696bdb","name":"Description","type":"plain_text"}],"itemById":{"30190aa4-5121-4522-b6d4-aad83e666e9e":{"id":"30190aa4-5121-4522-b6d4-aad83e666e9e","index":"\"","collectionId":"c94d0566-82dc-4df5-b63f-8746938a46da","fields":[{"id":"3045b7a8-be6e-46cb-9a4f-940904c1a7d7","value":"Three DxTerity Abstracts Accepted for Presentation at ACR Convergence 2026","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"b75c275d-e282-4e1a-841a-992d0d66c1da"},{"id":"67b5cd4e-0803-4f91-b1cb-48892e1330cb","value":"2026-09-08","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"ef193eef-561d-489f-9350-39bd897eb652"},{"id":"e7ec4d64-b211-4b32-b9ca-78274895957f","value":"Studies examine the Type I interferon gene signature and a low-density granulocyte neutrophil signature as tools for identifying lupus patients with severe disease, inadequate response to standard of care, and signs of resistance to anifrolumab therapy","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"6f2f7e7b-089a-466a-9e25-ad26df696bdb"},{"id":"40c0253c-d055-4047-a053-30b647e19d02","value":"Company","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"f7fc8c5b-ff56-4aef-a73a-481c7cc7bcb9"},{"id":"4781700c-c6b4-46f0-bab7-d9afa82e52b1","value":"{\"image\":\"c5538f42bacbd9089b018862331b6333bc5af9d8\",\"imageThumbnail\":\"8348e23498678bc67f790e97f35c48917bc58359\",\"originalImageHeight\":941,\"originalImageWidth\":1672,\"altText\":\"\",\"fileName\":\"Focused Research in a Modern Laboratory.png\"}","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"200f29aa-6f6f-4d59-b2bf-4203c876802f"},{"id":"7de04d4f-7915-44a3-9caf-aabaafd3b02d","value":"{\"root\":{\"children\":[{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"DxTerity today announced that three abstracts featuring the company’s RNA-based immune monitoring technology have been accepted for presentation at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, taking place November 6–11, 2026 at the Orange County Convention Center in Orlando, Florida.\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"The three abstracts apply RNA gene signature measurement to systemic lupus erythematosus (SLE), a disease in which clinical presentation and treatment response vary widely between patients. Together they examine whether molecular signatures of immune activity can help identify which patients are likely to have severe disease, which are responding inadequately to standard of care, and which show signs of resistance to targeted interferon-blocking therapy.\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Accepted Abstracts\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h3\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"1. The Type I Interferon (IFN-1) Gene Signature Identifies Systemic Lupus Erythematosus Patients More Likely to Have Severe Disease Including Activity in Immunologic, Renal and Hematologic Domains\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Demonstrated in a cohort of 943 samples from 395 SLE patients that IFN-1 High patients were more 3 times more likely to have Immunologic (Positive for dsDNA and Low Complement) symptoms, and 2 times more likely to have renal symptoms and active lupus nephritis than IFN-1 low patients (p\u003c0.0001).\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"2. Low Density Granulocyte Neutrophil Signature Identifies Systemic Lupus Erythematosus\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Patients with Inadequate Response to Standard of Care Treatment\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Demonstrated in a cohort of 395 SLE patients, at time of initial enrollment in the study, patients that were LDG-Neutrophil high were 4 times more likely to have active lupus nephritis and 28 times less likely to be in the Prevalent cohort with well managed disease (p\u003c0.0001).\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"3. Monitoring the Biological Response to Anifrolumab in Real World Setting Using Interferon Gene Signature Shows Signs of Therapy Resistance in Select SLE Patients\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Uses serial Type I Interferon gene signature measurements (IFN-1 testing) in a cohort of 17 patients being treated with the interferon receptor blocking drug anifrolumab, 2 patients showed loss of drug efficacy based on increasing IFN-1 score and return to IFN-1 high, while 1 patient is showing initialsigns of therapy resistance due to increasing IFN-1 score. Both IFN-1 high patients experienced disease flares.\",\"type\":\"text\",\"version\":1},{\"type\":\"linebreak\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Presentation Details\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Meeting: \",\"type\":\"text\",\"version\":1},{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"ACR Convergence 2026, American College of Rheumatology\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Venue: \",\"type\":\"text\",\"version\":1},{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Orange County Convention Center, Orlando, Florida\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Session: \",\"type\":\"text\",\"version\":1},{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Poster Session C\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Date: \",\"type\":\"text\",\"version\":1},{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Tuesday, November 10, 2026\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Time: \",\"type\":\"text\",\"version\":1},{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"10:30 a.m. – 12:30 p.m. ET\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":1,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":3,\"mode\":\"normal\",\"style\":\"\",\"text\":\"“Exciting to see the growth in evidence on the utility of modular assessment of immune health leveraging\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":3,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":3,\"mode\":\"normal\",\"style\":\"\",\"text\":\"our Modular Immune Profile Assay. Grateful for the contributions and guidance of all our collaborators at\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":3,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":3,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Lupus Research Alliance.” \",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":3,\"tag\":\"h4\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"said Bob Terbrueggen, CEO of DxTerity.\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"Full abstract text will be available through the ACR Convergence online program. DxTerity representatives will be available at the meeting to discuss the data and the company’s immune monitoring programs.\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":1,\"mode\":\"normal\",\"style\":\"\",\"text\":\"About DxTerity\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"heading\",\"version\":1,\"textFormat\":1,\"tag\":\"h6\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being. DxTerity’s Type 1 Interferon (IFN-1) and Modular Immune Profile tests are run in the company’s CAP-accredited, CLIA-certified laboratory in Torrance, California. DxTerity also holds ISO 13485 certification for its product\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"detail\":0,\"format\":0,\"mode\":\"normal\",\"style\":\"\",\"text\":\"development services.\",\"type\":\"text\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"},{\"children\":[{\"type\":\"linebreak\",\"version\":1}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"paragraph\",\"version\":1,\"textFormat\":0,\"textStyle\":\"\"}],\"direction\":null,\"format\":\"\",\"indent\":0,\"type\":\"root\",\"version\":1,\"textFormat\":1}}","itemId":"30190aa4-5121-4522-b6d4-aad83e666e9e","fieldSchemaId":"62fe7219-3878-49d9-a8af-86d06cba35bb"}]}}},"ae03358f-f7b8-4973-9ea0-969bc81f18d9":{"id":"ae03358f-f7b8-4973-9ea0-969bc81f18d9","name":"Regular articles","fieldSchemas":[{"id":"6690ab56-675e-4a5b-a95b-7ed858c6dd7b","name":"Title","type":"plain_text","role":"primary"},{"id":"3247e351-f412-43af-bca3-161d995c0738","name":"Slug","type":"slug","role":"slug"},{"id":"421ec6f8-afd5-458e-ace6-3c68d1b73f4a","name":"Image","type":"image"},{"id":"e9ce536b-3dec-4310-8ea9-0f0cb5cb0c37","name":"Date","type":"date"},{"id":"fd26dd7d-05a0-49ca-b0ee-a3cc8f978d13","name":"Category","type":"plain_text"},{"id":"b30d34fa-5240-4c93-af2b-ec44429f6880","name":"Description","type":"plain_text"}],"itemById":{"751f8d1a-4b21-4227-82e1-a4721b9efa72":{"id":"751f8d1a-4b21-4227-82e1-a4721b9efa72","index":"~O7","collectionId":"ae03358f-f7b8-4973-9ea0-969bc81f18d9","fields":[{"id":"0a097b61-55d5-46d6-b1b8-74f93ff286db","value":"precision-medicine-using-modular-genomics","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"3247e351-f412-43af-bca3-161d995c0738"},{"id":"55a05ce0-26ce-4bfe-a06c-70dce8d457f5","value":"2026-05-14","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"e9ce536b-3dec-4310-8ea9-0f0cb5cb0c37"},{"id":"ce7df6fa-cf01-489f-8d49-d0b624f4fe89","value":"Research","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"fd26dd7d-05a0-49ca-b0ee-a3cc8f978d13"},{"id":"22b1688b-5b98-4729-b190-10a05fcdc535","value":"{\"image\":\"e4d434d21000db5952ca90b4ded9a33367c3d424\",\"imageThumbnail\":\"fec43c3aaa89f05c8cebd9e1dcae3584ac696670\",\"originalImageHeight\":928,\"originalImageWidth\":1232,\"altText\":\"\",\"fileName\":\"anifrilamab inviting.jpg\"}","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"421ec6f8-afd5-458e-ace6-3c68d1b73f4a"},{"id":"1aa9abd9-8748-49f9-9a77-a0ee986f729e","value":"A simple look at how RNA-based testing can help uncover patterns in immune system activity and support more informed care decisions.","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"b30d34fa-5240-4c93-af2b-ec44429f6880"},{"id":"f9552f14-2e7d-4951-8cb4-e06b42de66ee","value":"Precision Medicine using Modular Genomics","itemId":"751f8d1a-4b21-4227-82e1-a4721b9efa72","fieldSchemaId":"6690ab56-675e-4a5b-a95b-7ed858c6dd7b"}]},"cdf70363-4d8e-45ef-ba24-1fc7df953ead":{"id":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","index":"~O","collectionId":"ae03358f-f7b8-4973-9ea0-969bc81f18d9","fields":[{"id":"64736e88-9426-45f9-9ce2-ca8d04f2a00b","value":"{\"image\":\"3eb2007290d0ee2ca610b57cb8de129d4ee91fbe\",\"imageThumbnail\":\"3e8b7a0871d9ed9c335665d56fe2e4af62fa3310\",\"originalImageHeight\":4773,\"originalImageWidth\":8379,\"altText\":\"\",\"fileName\":\"iStock-491360572_super.jpg\"}","itemId":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","fieldSchemaId":"421ec6f8-afd5-458e-ace6-3c68d1b73f4a"},{"id":"cc5359b3-be61-4bd2-91b4-e0d256ea3311","value":"IFN-1 gene signature testing represents the advancement of precision medicine beyond cancer in autoimmune disease","itemId":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","fieldSchemaId":"b30d34fa-5240-4c93-af2b-ec44429f6880"},{"id":"e4c2b8dc-7668-4735-a96d-d6af6b463556","value":"DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) for Systemic Lupus Erythematosus","itemId":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","fieldSchemaId":"6690ab56-675e-4a5b-a95b-7ed858c6dd7b"},{"id":"78cfa45a-6162-4921-aaec-b40e02066b18","value":"2022-05-18","itemId":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","fieldSchemaId":"e9ce536b-3dec-4310-8ea9-0f0cb5cb0c37"},{"id":"80be6361-1e98-4cf1-ac7f-4a0b6fd8a807","value":"dxterity-receives-new-york-authorization-for-type-1-interferon-ifn-1-for-systemic-lupus-erythematosu","itemId":"cdf70363-4d8e-45ef-ba24-1fc7df953ead","fieldSchemaId":"3247e351-f412-43af-bca3-161d995c0738"}]},"e9941f4c-d4f1-4327-9c21-615339d0595b":{"id":"e9941f4c-d4f1-4327-9c21-615339d0595b","index":"~OO","collectionId":"ae03358f-f7b8-4973-9ea0-969bc81f18d9","fields":[{"id":"e2b0596b-b4aa-4921-b8b5-698ea0e1f11d","value":"DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"6690ab56-675e-4a5b-a95b-7ed858c6dd7b"},{"id":"aa442b4f-f9c1-48c8-a4a1-03a54067ce00","value":"Research","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"fd26dd7d-05a0-49ca-b0ee-a3cc8f978d13"},{"id":"5dfa73b2-f89a-4642-b012-ee3969d07648","value":"2020-02-27","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"e9ce536b-3dec-4310-8ea9-0f0cb5cb0c37"},{"id":"a53ea959-91a7-4b06-833e-7cc99ac8ae1b","value":"{\"image\":\"f47d74722873d53484ace1c153867532f0ea9e9e\",\"imageThumbnail\":\"d2670476229c1cabedd16be021ac57c120c3ce36\",\"originalImageHeight\":1840,\"originalImageWidth\":3842,\"altText\":\"\",\"fileName\":\"Hero_1.png\"}","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"421ec6f8-afd5-458e-ace6-3c68d1b73f4a"},{"id":"8c763d13-83d1-48fc-b3ae-ebf04a580fb1","value":"Learn how patient-friendly testing can reduce barriers, improve convenience, and help people stay more connected to their health journey.","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"b30d34fa-5240-4c93-af2b-ec44429f6880"},{"id":"c1afeec0-fe6c-4ffe-a852-2d6ce82a2185","value":"dxterity-seeks-to-deliver-meaningful-guidance-to-patients-and-physicians-from-the-conveinace-of-home","itemId":"e9941f4c-d4f1-4327-9c21-615339d0595b","fieldSchemaId":"3247e351-f412-43af-bca3-161d995c0738"}]}}}},"slugByItemId":{"e63e79ef-9384-494b-a3dc-bda6a026ebb5":"the-landmark-study-is-targeting-the-prospective-enrollment-of-up-to-3500-adults-diagnosed-with-syste","30190aa4-5121-4522-b6d4-aad83e666e9e":"three-dxterity-abstracts-accepted-for-presentation-at-acr-convergence-2026","7146f193-b365-4288-915c-f0a008c2af6d":"dxterity-opens-purpose-built-torrance-headquarters-and-laboratory","e9941f4c-d4f1-4327-9c21-615339d0595b":"dxterity-seeks-to-deliver-meaningful-guidance-to-patients-and-physicians-from-the-conveinace-of-home","cdf70363-4d8e-45ef-ba24-1fc7df953ead":"dxterity-receives-new-york-authorization-for-type-1-interferon-ifn-1-for-systemic-lupus-erythematosu","751f8d1a-4b21-4227-82e1-a4721b9efa72":"precision-medicine-using-modular-genomics"}}